<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5849279</article-id><article-id pub-id-type="doi">10.1371/journal.pmed.1002525</article-id><article-id pub-id-type="publisher-id">PMEDICINE-D-17-02773</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Arrhythmia</subject><subj-group><subject>Atrial Fibrillation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular Diseases</subject><subj-group><subject>Stroke</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Stroke</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Materials Science</subject><subj-group><subject>Materials by Attribute</subject><subj-group><subject>Adhesives</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Bioassays and Physiological Analysis</subject><subj-group><subject>Electrophysiological Techniques</subject><subj-group><subject>Cardiac Electrophysiology</subject><subj-group><subject>Electrocardiography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Blood Pressure</subject><subj-group><subject>Hypertension</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Myocardial Infarction</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Heart Failure</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Validation of a genetic risk score for atrial fibrillation: A prospective multicenter cohort study</article-title><alt-title alt-title-type="running-head">Genetic risk score for atrial fibrillation</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5288-7462</contrib-id><name><surname>Muse</surname><given-names>Evan D.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wineinger</surname><given-names>Nathan E.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2650-4357</contrib-id><name><surname>Spencer</surname><given-names>Emily G.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peters</surname><given-names>Melissa</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Henderson</surname><given-names>Riley</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9873-6694</contrib-id><name><surname>Zhang</surname><given-names>Yunyue</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barrett</surname><given-names>Paddy M.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rivera</surname><given-names>Steven P.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wohlgemuth</surname><given-names>Jay G.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Devlin</surname><given-names>James J.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shiffman</surname><given-names>Dov</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Topol</surname><given-names>Eric J.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, California, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Division of Cardiovascular Disease, Scripps Clinic&#x02013;Scripps Health, La Jolla, California, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Quest Diagnostics, San Juan Capistrano, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Rahimi</surname><given-names>Kazem</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Oxford, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>JGW is an employee of Quest Diagnostics and receives stock and stock options from Quest Diagnostics. SPR, JJD and DS are employees of Quest Diagnostics.</p></fn><corresp id="cor001">* E-mail: <email>etopol@scripps.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2018</year></pub-date><volume>15</volume><issue>3</issue><elocation-id>e1002525</elocation-id><history><date date-type="received"><day>8</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>6</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Muse et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Muse et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pmed.1002525.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Atrial fibrillation (AF) is the most commonly encountered arrhythmia and is associated with an elevated risk of stroke. Improving the identification of patients with the highest risk for AF to enable appropriate surveillance and treatment, if necessary, is critical to reducing AF-associated morbidity and mortality. Multiple common single nucleotide polymorphisms (SNPs) are unequivocally associated with the lifetime risk of AF. In the current study we aimed to prospectively validate an AF genetic risk score (GRS) in previously undiagnosed patients at risk for AF.</p></sec><sec id="sec002"><title>Methods and findings</title><p>Individuals 40 years of age or older with 1 clinical risk factor for AF, presenting with symptoms of AF, or with a first diagnosis of AF, were enrolled for genetic testing and ambulatory cardiac rhythm monitoring with an adhesive patch monitor or a long-term Holter monitor (mean wear time 10 days 21 hours and 13 days 18 hours, respectively). An AF event was the first diagnosis of AF by ECG, patch monitor, or long-term Holter monitor. The AF GRS was determined for each participant based on the weighted contribution of 12 genetic risk loci. Of 904 participants, 85 manifested AF. Their mean age was 66.2 (SD 11.8) years; 38% of participants were male. Participants in the highest quintile of AF GRS were more likely (odds ratio 3.11; 95% CI 1.27&#x02013;7.58; <italic>p =</italic> 0.01) to have had an AF event than participants in the lowest quintile after adjusting for age, sex, smoking status, BMI, hypertension, diabetes mellitus, heart failure, and prior myocardial infarction. Study limitations included an ethnically homogenous population, a restricted rhythm monitoring period, and the evolving discovery of SNPs associated with AF.</p></sec><sec id="sec003"><title>Conclusions</title><p>Prospective assessment of a GRS for AF identified participants with elevated risk of AF beyond established clinical criteria. Accordingly, a GRS for AF could be incorporated into overall risk assessment to better identify patients at the highest risk of developing AF, although further testing in larger populations is needed to confirm these findings.</p></sec><sec id="sec004"><title>Trial registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01970969">NCT01970969</ext-link></p></sec></abstract><abstract abstract-type="toc"><p>In prospective cohort study, Eric Topol and colleague validate a genetic risk score for identification of patients at the highest risk of developing atrial fibrillation.</p></abstract><abstract abstract-type="summary"><title>Author summary</title><sec id="sec005"><title>Why was this study done?</title><list list-type="bullet"><list-item><p>Atrial fibrillation (AF) is a common heart rhythm disturbance that can lead to devastating strokes.</p></list-item><list-item><p>While clinical factors such as age, high blood pressure, and obesity can increase the chances of developing AF, several genetic determinants of AF also play a role.</p></list-item><list-item><p>Here we assessed the ability of a genetic risk score (GRS) for AF to identify individuals presenting with symptoms with the highest likelihood of AF on cardiac rhythm monitoring.</p></list-item></list></sec><sec id="sec006"><title>What did the researchers do and find?</title><list list-type="bullet"><list-item><p>Individuals 40 years of age or older with at least 1 clinical risk factor for AF presenting either with symptoms of AF or with the first diagnosis of AF on electrocardiogram were enrolled.</p></list-item><list-item><p>A patch-based or long-term Holter cardiac rhythm monitor was fitted to individuals without AF on electrocardiogram, and they were monitored for upwards of 2 weeks.</p></list-item><list-item><p>DNA was isolated from a blood sample, and an AF GRS was calculated for each participant.</p></list-item><list-item><p>We found that individuals with the highest AF GRSs were 3 times more likely to be diagnosed with AF during the study than participants with the lowest AF GRSs.</p></list-item></list></sec><sec id="sec007"><title>What do these findings mean?</title><list list-type="bullet"><list-item><p>An AF GRS may be incorporated into an overall risk assessment strategy to better identify patients at the highest risk of developing AF.</p></list-item><list-item><p>For patients with stroke of unknown origin, a high AF GRS may be helpful to guide diagnostic testing.</p></list-item><list-item><p>In the future, individuals with high AF genomic risk may be able to use this information to help prevent the arrhythmia from occurring.</p></list-item></list></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>UL1 TR001114</award-id><principal-award-recipient><name><surname>Topol</surname><given-names>Eric J.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>KL2 TR001112</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5288-7462</contrib-id><name><surname>Muse</surname><given-names>Evan D.</given-names></name></principal-award-recipient></award-group><funding-statement>National Institute of Health, National Center for Advancing Translational Science. UL1TR001114 (EJT); National Institute of Health, National Center for Advancing Translational Science. KL2 TR001112 (EDM); Quest Diagnostics, Inc. (SPR, JGW, JJD, DS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="3"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec008"><title>Introduction</title><p>Stroke remains the fifth leading cause of death in the United States, despite increased recognition and better management of overall cardiovascular disease risk, which has led to a decline in stroke mortality [<xref rid="pmed.1002525.ref001" ref-type="bibr">1</xref>]. More than 750,000 people experience a stroke event each year in the US, with a prevalence of 2.6% in the US adult population [<xref rid="pmed.1002525.ref001" ref-type="bibr">1</xref>]. While conventional risk factors for stroke&#x02014;including cigarette smoking, hypertension, diabetes mellitus, dyslipidemia, and heart failure&#x02014;account for a sizable portion of stroke episodes, atrial fibrillation (AF) is associated with a quarter of all stroke events [<xref rid="pmed.1002525.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pmed.1002525.ref004" ref-type="bibr">4</xref>].</p><p>AF is the most common pathological cardiac arrhythmia, present in nearly 6 million people in the US alone, with the prevalence estimated to grow to over 12 million people by 2030 [<xref rid="pmed.1002525.ref005" ref-type="bibr">5</xref>]. It is not uncommon for AF to remain undetected in asymptomatic individuals. AF has been documented in asymptomatic individuals not only in patients with implanted cardiac devices [<xref rid="pmed.1002525.ref006" ref-type="bibr">6</xref>,<xref rid="pmed.1002525.ref007" ref-type="bibr">7</xref>], but also in population-based screening studies using smartphone electrocardiogram (ECG) sensors [<xref rid="pmed.1002525.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pmed.1002525.ref011" ref-type="bibr">11</xref>]. These efforts to better diagnose subclinical, asymptomatic AF may be useful for implementing appropriate therapies to reduce the risk of stroke [<xref rid="pmed.1002525.ref012" ref-type="bibr">12</xref>].</p><p>To this end, efforts have been made to predict the occurrence of AF using risk scores based on clinical factors associated with disease [<xref rid="pmed.1002525.ref013" ref-type="bibr">13</xref>,<xref rid="pmed.1002525.ref014" ref-type="bibr">14</xref>]. While clinical risk factors for AF (e.g., obesity, hypertension, and obstructive sleep apnea) are well established, risk scores incorporating these factors have fallen short in validation studies [<xref rid="pmed.1002525.ref015" ref-type="bibr">15</xref>]. Therefore, efforts continue to improve risk prediction by incorporating genetic risk factors. Genetic factors are estimated to account for ~40% of a person&#x02019;s total AF risk [<xref rid="pmed.1002525.ref016" ref-type="bibr">16</xref>], and genome-wide association studies (GWASs) of increasing size have identified multiple single nucleotide polymorphisms (SNPs) associated with AF on the genome-wide level [<xref rid="pmed.1002525.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pmed.1002525.ref023" ref-type="bibr">23</xref>]. For AF, several genetic risk scores (GRSs) have been characterized and tested in various studies, illustrating their ability to identify individuals at increased risk of AF [<xref rid="pmed.1002525.ref024" ref-type="bibr">24</xref>&#x02013;<xref rid="pmed.1002525.ref029" ref-type="bibr">29</xref>]. But some of these findings pertain to a lifetime risk of AF or &#x0003e;14 years of follow-up, and have not yet provided any insight on immediate risk for an individual with established risk factors presenting with symptoms.</p><p>Here, in this multicenter study of symptomatic participants without prior diagnosis of AF, we aimed to prospectively validate a 12-SNP AF GRS for identifying patients at an increased risk for AF during 2 weeks of ambulatory cardiac rhythm monitoring.</p></sec><sec sec-type="materials|methods" id="sec009"><title>Methods</title><sec id="sec010"><title>Participant recruitment and inclusion and exclusion criteria</title><p>The study was approved by the institutional review board (IRB) at the Scripps Clinic (La Jolla, CA), which provided overall study oversight, in addition to the individual IRBs affiliated with each recruitment center. Participants were enrolled from December 2, 2013, through January 19, 2016. The complete list of recruitment centers is provided in <xref ref-type="supplementary-material" rid="pmed.1002525.s004">S1 Table</xref>. Informed consent was provided by each patient prior to enrollment. Patients presenting with any symptoms suggestive of AF determined by the clinician to necessitate ambulatory cardiac rhythm monitoring were evaluated for inclusion in this study. Patients were eligible for enrollment if they were 40 years of age or older and were capable of providing informed consent in addition to providing a blood sample for genetic analysis. Study participants were also required to have at least 1 of the following clinical characteristics: hypertension, ischemic stroke with no defined etiology within the past 6 months, high BMI (&#x0003e;30 kg/m<sup>2</sup>), history of heart failure, clinically significant murmur, first degree atrioventricular block (PR interval &#x0003e; 200 ms), chronic kidney disease, hypertrophic cardiomyopathy, congenital heart disease, chronic obstructive pulmonary disease, obstructive sleep apnea, diabetes mellitus, regular excess alcohol consumption (males &#x0003e;14 drinks/week, females &#x0003e;7 drinks/week), or a family history of AF. Patients with a prior diagnosis of AF or atrial flutter were excluded. Additionally, patients with cardiac surgery (coronary artery bypass grafting, valve replacement or repair, pericardial stripping, etc.) within the previous 30 days, with hyperthyroidism, receiving permanent pacing therapy, with skin allergies or sensitivities to adhesives, or who were anticipated to have exposure to high frequency surgical equipment during the monitoring period were not eligible for enrollment. An independent data and safety monitoring board provided ongoing study oversight throughout the trial period. This study (<xref ref-type="supplementary-material" rid="pmed.1002525.s003">S1 Protocol</xref>) was registered with ClinicalTrials.gov (NCT01970969) and is reported as per the TRIPOD guidelines (<xref ref-type="supplementary-material" rid="pmed.1002525.s001">S1 Checklist</xref>).</p></sec><sec id="sec011"><title>Cardiac rhythm monitoring and event adjudication</title><p>The primary event was an instance of AF/atrial flutter as defined by standard electrocardiographic criteria for a minimum duration of 5 seconds (AF event). AF events were assessed either by ambulatory cardiac rhythm monitoring or on 12-lead ECG. Patients meeting the specified inclusion criteria presenting to an outpatient clinic for evaluation of symptoms with high clinical suspicion for AF were either provided an adhesive patch monitor (Zio patch, iRhythm Technologies), if enrolled at centers within the US, or fitted with a long-term Holter monitor (Spiderflash, Soren Group) at Canadian centers. Participants were instructed to wear the cardiac rhythm monitor for the life of the device (~2 weeks). Symptomatic patients presenting with the first diagnosis of AF on 12-lead ECG were not required to have additional ambulatory cardiac rhythm monitoring. Events that were considered possible occurrences of AF were independently adjudicated by 2 separate physicians with expertise in cardiac rhythm interpretation, with a third physician&#x02019;s review available for incongruent cases.</p></sec><sec id="sec012"><title>Genotyping</title><p>DNA was extracted from whole blood using the MagNA Pure 96 instrument and reagent kit (Roche Life Science). SNaPshot multiplex genotyping (Thermo Fisher Scientific) was used to simultaneously genotype 12 SNPs comprising the AF GRS (<xref ref-type="table" rid="pmed.1002525.t001">Table 1</xref>).</p><table-wrap id="pmed.1002525.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1002525.t001</object-id><label>Table 1</label><caption><title>Single nucleotide polymorphisms associated with AF used for the determination of the AF GRS.</title></caption><alternatives><graphic id="pmed.1002525.t001g" xlink:href="pmed.1002525.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">SNP</th><th align="left" rowspan="1" colspan="1">Modeled allele</th><th align="left" rowspan="1" colspan="1">MAF</th><th align="left" rowspan="1" colspan="1">Weight</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1q21</td><td align="left" rowspan="1" colspan="1"><italic>KCNN3</italic></td><td align="left" rowspan="1" colspan="1">rs13376333</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">1q24</td><td align="left" rowspan="1" colspan="1"><italic>PRRX1</italic></td><td align="left" rowspan="1" colspan="1">rs3903239</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">4q25</td><td align="left" rowspan="1" colspan="1"><italic>PITX2</italic></td><td align="left" rowspan="1" colspan="1">rs10033464</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">4q25</td><td align="left" rowspan="1" colspan="1"><italic>PITX2</italic></td><td align="left" rowspan="1" colspan="1">rs17570669</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">&#x02212;0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">4q25</td><td align="left" rowspan="1" colspan="1"><italic>PITX2</italic></td><td align="left" rowspan="1" colspan="1">rs2200733</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">4q25</td><td align="left" rowspan="1" colspan="1"><italic>PITX2</italic></td><td align="left" rowspan="1" colspan="1">rs3853445</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">&#x02212;0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">7q31</td><td align="left" rowspan="1" colspan="1"><italic>CAV1</italic></td><td align="left" rowspan="1" colspan="1">rs3807989</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">&#x02212;0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">9q22</td><td align="left" rowspan="1" colspan="1"><italic>C9orf3</italic></td><td align="left" rowspan="1" colspan="1">rs10821415</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">10q22</td><td align="left" rowspan="1" colspan="1"><italic>SYNPO2L</italic></td><td align="left" rowspan="1" colspan="1">rs10824026</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">&#x02212;0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">14q23</td><td align="left" rowspan="1" colspan="1"><italic>SYNE2</italic></td><td align="left" rowspan="1" colspan="1">rs1152591</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.46</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">15q24</td><td align="left" rowspan="1" colspan="1"><italic>HCN4</italic></td><td align="left" rowspan="1" colspan="1">rs7164883</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">16q22</td><td align="left" rowspan="1" colspan="1"><italic>ZFHX3</italic></td><td align="left" rowspan="1" colspan="1">rs2106261</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">0.22</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>AF, atrial fibrillation; GRS, genetic risk score; MAF, mean allele frequency; SNP, single nucleotide polymorphism.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec013"><title>Modeling of GRS and statistical analyses</title><p>Comparisons of baseline characteristics between patients with and without detected AF were conducted using chi-squared and <italic>t</italic> tests for categorical and quantitative traits, respectively. We sought to validate an existing 12-SNP AF GRS that had previously been examined in a retrospective manner [<xref rid="pmed.1002525.ref027" ref-type="bibr">27</xref>]. The AF GRS in this study was calculated using a weighted allele-counting approach from previously reported weights [<xref rid="pmed.1002525.ref027" ref-type="bibr">27</xref>] (<xref ref-type="table" rid="pmed.1002525.t001">Table 1</xref>). Expected AF events in the 2 groups were calculated using reference to previous studies [<xref rid="pmed.1002525.ref030" ref-type="bibr">30</xref>,<xref rid="pmed.1002525.ref031" ref-type="bibr">31</xref>]. We expected roughly 80 AF events in 1,000 at-risk patients. Using this event rate, and based on a simulation in which the absolute rate of AF increased by 2% per AF GRS quintile (AF rate is half the population average in the lowest quintile and 1.5 times the population average in the highest quintile), we had 90% power to detect an association between AF GRS quintile and AF at an alpha of 5% (<xref ref-type="supplementary-material" rid="pmed.1002525.s002">S1 Text</xref>). To account for the small number of missing genotype data (15 genotypes, 0.14% missing rate across all markers), missing genotypes were replaced with the average genotype at that marker based on additive coding. The association between AF GRS and newly detected AF was assessed using logistic regression. Two approaches to model AF GRS were used: (1) coding the AF GRS as a quantitative, continuous variable and (2) coding the AF GRS as a quantitative variable using quintile categories. Results are presented conditional (adjusted) and not conditional (unadjusted) for the following covariates: age, sex, smoking status, BMI, the presence of diabetes mellitus, and history of hypertension, myocardial infarction, and heart failure. All analyses were performed in R version 3.2.3 (R Project for Statistical Computing).</p></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><sec id="sec015"><title>Patient characteristics</title><p>A total of 934 participants were enrolled from December 2, 2013, through January 19, 2016. The final analysis excluded 30 participants who did not provide a blood sample for genotyping, were missing adhesive patch monitor data, or had a prior diagnosis of AF identified upon chart review. Accounting for these exclusions, the final analysis included 904 participants. A total of 85 participants were discovered to have AF from the adhesive patch monitor (<italic>n</italic> = 44) or ECG (<italic>n</italic> = 41) during the study. The mean wear time was 10 days and 21 hours for the adhesive patch monitors and 13 days and 18 hours for the long-term Holter monitors. There was no difference in wear time between participants with and without the diagnosis of AF (<italic>p =</italic> 0.49). The primary presenting indication for which cardiac rhythm monitoring was pursued was palpitations/tachycardia (72%), followed by syncope/near-syncope (14%), transient ischemic attack/stroke (9%), and chest pain/dyspnea (5%).</p><p>Baseline characteristics for participants with and without AF are provided in <xref ref-type="table" rid="pmed.1002525.t002">Table 2</xref>. The self-reported ethnicity of participants was predominantly white (92.6%), with other ethnicities including African-American (5.2%), Asian (1.7%), and Native American (0.2%). The mean age for participants with AF (68.5 years [SD 11.2]) was greater than for participants without AF (65.9 years [SD 11.8], <italic>p =</italic> 0.046). Men made up the majority of participants with AF (52%) and the minority for participants without AF (36%). Participants with AF had a higher mean BMI (31.7 kg/m<sup>2</sup>) than the group without AF (29.4 kg/m<sup>2</sup>, <italic>p =</italic> 0.02), but the prevalence of diabetes was lower (13% for those with AF compared with 23% for those without AF, <italic>p =</italic> 0.04). There were no intergroup differences in the prevalence of the other comorbidities evaluated. Additionally, the stroke risk as evaluated by CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores did not differ between the 2 groups.</p><table-wrap id="pmed.1002525.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1002525.t002</object-id><label>Table 2</label><caption><title>Baseline characteristics.</title></caption><alternatives><graphic id="pmed.1002525.t002g" xlink:href="pmed.1002525.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">No AF (<italic>n</italic> = 819)</th><th align="left" rowspan="1" colspan="1">AF (<italic>n</italic> = 85)</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">65.9 (11.8)</td><td align="left" rowspan="1" colspan="1">68.5 (11.2)</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">297 (36%)</td><td align="left" rowspan="1" colspan="1">44 (52%)</td><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">755 (92%)</td><td align="left" rowspan="1" colspan="1">82 (96%)</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker</td><td align="left" rowspan="1" colspan="1">78 (9.5%)</td><td align="left" rowspan="1" colspan="1">6 (7.1%)</td><td align="left" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (m)</td><td align="left" rowspan="1" colspan="1">1.69 (0.10)</td><td align="left" rowspan="1" colspan="1">1.72 (0.12)</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="left" rowspan="1" colspan="1">83.9 (20.9)</td><td align="left" rowspan="1" colspan="1">93.4 (26.6)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">29.4 (6.6)</td><td align="left" rowspan="1" colspan="1">31.7 (8.5)</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">626 (76%)</td><td align="left" rowspan="1" colspan="1">67 (79%)</td><td align="left" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI &#x0003e; 30 kg/m<sup>2</sup></td><td align="left" rowspan="1" colspan="1">305 (37%)</td><td align="left" rowspan="1" colspan="1">44 (52%)</td><td align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypothyroidism</td><td align="left" rowspan="1" colspan="1">194 (24%)</td><td align="left" rowspan="1" colspan="1">15 (18%)</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">190 (23%)</td><td align="left" rowspan="1" colspan="1">11 (13%)</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Obstructive sleep apnea</td><td align="left" rowspan="1" colspan="1">157 (19%)</td><td align="left" rowspan="1" colspan="1">22 (26%)</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Family history of AF</td><td align="left" rowspan="1" colspan="1">137 (17%)</td><td align="left" rowspan="1" colspan="1">20 (24%)</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">History of MI</td><td align="left" rowspan="1" colspan="1">73 (9%)</td><td align="left" rowspan="1" colspan="1">7 (8%)</td><td align="left" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic stroke or TIA (within past 6 months)</td><td align="left" rowspan="1" colspan="1">72 (9%)</td><td align="left" rowspan="1" colspan="1">6 (7%)</td><td align="left" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="left" rowspan="1" colspan="1">77 (8%)</td><td align="left" rowspan="1" colspan="1">10 (12%)</td><td align="left" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Excess alcohol consumption</td><td align="left" rowspan="1" colspan="1">63 (8%)</td><td align="left" rowspan="1" colspan="1">12 (14%)</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">History of heart failure</td><td align="left" rowspan="1" colspan="1">41 (5%)</td><td align="left" rowspan="1" colspan="1">8 (9%)</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic kidney disease</td><td align="left" rowspan="1" colspan="1">36 (4%)</td><td align="left" rowspan="1" colspan="1">5 (6%)</td><td align="left" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">CHADS2 score</td><td align="left" rowspan="1" colspan="1">1.6 (1.2)</td><td align="left" rowspan="1" colspan="1">1.6 (1.2)</td><td align="left" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">CHADS2VASc score</td><td align="left" rowspan="1" colspan="1">2.9 (1.6)</td><td align="left" rowspan="1" colspan="1">2.8 (1.6)</td><td align="left" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Patch monitor wear time, mean</td><td align="left" rowspan="1" colspan="1">10 d 21 h</td><td align="left" rowspan="1" colspan="1">11 d 4 h</td><td align="left" rowspan="1" colspan="1">0.49</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Data are given as mean (SD) or <italic>n</italic> (percent), unless otherwise indicated.</p></fn><fn id="t002fn002"><p>AF, atrial fibrillation; BMI, body mass index; MI, myocardial infarction; SD, standard deviation; TIA, transient ischemic attack.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec016"><title>AF GRS and AF events</title><p>The AF GRS was calculated as a weighted sum of the 12 SNPs (<xref ref-type="table" rid="pmed.1002525.t001">Table 1</xref>) for each participant based on their genotype for these SNPS, and the scores ranged from &#x02212;0.84 to 1.78. The mean AF GRS for the 85 participants diagnosed with AF during the study was significantly higher than the mean AF GRS for the 819 participants without AF (mean [SD]: 0.582 [0.378] versus 0.439 [0.382], <italic>p =</italic> 0.001). The incidence of AF increased across increasing quintiles of AF GRS (<xref ref-type="table" rid="pmed.1002525.t003">Table 3</xref>), with the odds per SD increase in AF GRS increasing by a factor of 1.43 (95% CI 1.15&#x02013;1.77; <italic>p =</italic> 0.001). In an unadjusted analysis, participants in the highest quintile of AF GRS (&#x0003e;0.77) had an increased risk of having an AF event during the course of the study (odds ratio [OR] 2.83; 95% CI 1.21&#x02013;6.61; <italic>p =</italic> 0.02) as compared with participants in the lowest AF GRS quintile. After adjusting for age, sex, smoking status, BMI, diabetes mellitus, hypertension, prior myocardial infarction, and heart failure, the odds per SD increase in AF GRS increased by a factor of 1.45 (95% CI 1.16&#x02013;1.83; <italic>p =</italic> 0.001), with participants in the highest AF GRS quintile having greater than 3 times the odds (OR 3.11; 95% CI 1.27&#x02013;7.58; <italic>p =</italic> 0.01) of AF diagnosis compared with those at lowest AF GRS quintile (<xref ref-type="table" rid="pmed.1002525.t003">Table 3</xref>). Modeling AF GRS increased the C-statistic from 0.687 to 0.719 over a model that considered only age, sex, smoking status, BMI, diabetes mellitus, hypertension, prior myocardial infarction, and heart failure (<italic>p =</italic> 0.001). Additionally, when the AF GRS was assessed according to GRS tertiles, the highest AF GRS tertile had greater than 2 times the risk of an AF event compared to the lowest tertile (unadjusted OR 2.26; 95% CI 1.27&#x02013;4.01; <italic>p &#x0003c;</italic> 0.01; adjusted OR 2.32; 95% CI 1.28&#x02013;4.20; <italic>p =</italic> 0.006). Alternative time-to-event approaches are not presented due to the short AF monitoring period, though the results were consistent with the logisticregression results.</p><table-wrap id="pmed.1002525.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1002525.t003</object-id><label>Table 3</label><caption><title>Risk estimates of AF events according to AF GRS quintile (12 SNPs).</title></caption><alternatives><graphic id="pmed.1002525.t003g" xlink:href="pmed.1002525.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">AF GRS quintile</th><th align="left" rowspan="1" colspan="1">Unadjusted OR (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="left" rowspan="1" colspan="1">Adjusted<xref ref-type="table-fn" rid="t003fn002">*</xref> OR (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1 (<italic>n</italic> = 187)</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">2 (<italic>n</italic> = 177)</td><td align="left" rowspan="1" colspan="1">2.35 (0.94&#x02013;5.87)</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">2.37 (0.89&#x02013;6.30)</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">3 (<italic>n</italic> = 180)</td><td align="left" rowspan="1" colspan="1">2.48 (1.05&#x02013;5.87)</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">2.47 (0.98&#x02013;6.22)</td><td align="left" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" rowspan="1" colspan="1">4 (<italic>n</italic> = 182)</td><td align="left" rowspan="1" colspan="1">3.40 (1.48&#x02013;7.78)</td><td align="left" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">3.49 (1.48&#x02013;8.23)</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">5 (<italic>n</italic> = 178)</td><td align="left" rowspan="1" colspan="1">2.83 (1.21&#x02013;6.61)</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">3.11 (1.27&#x02013;7.58)</td><td align="left" rowspan="1" colspan="1">0.013</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>AF GRS quintile ranges: Q1 &#x02264; 0.14; Q2 &#x0003e; 0.14 and &#x02264; 0.33; Q3 &#x0003e; 0.33 and &#x02264; 0.50; Q4 &#x0003e; 0.50 and &#x02264; 0.77; Q5 &#x0003e; 0.77.</p></fn><fn id="t003fn002"><p>*Adjusted by age, sex, smoking status, BMI, diabetes, hypertension, prior myocardial infarction, and heart failure.</p></fn><fn id="t003fn003"><p>AF, atrial fibrillation; GRS, genetic risk score; CI, confidence interval; OR, odds ratio.</p></fn></table-wrap-foot></table-wrap><p>In an effort to examine the individual contributions of the 12 SNPs that composed the AF GRS, we evaluated the association of each SNP with AF in both unadjusted and adjusted models (<xref ref-type="supplementary-material" rid="pmed.1002525.s005">S2 Table</xref>), though this study was not well powered to detect individual marker effects. Eleven of the 12 SNPs were consistent with prior results: either the direction of the effect allele was consistent with previous reports, or the result was not nominally significant (<italic>p &#x0003c;</italic> 0.05). However, rs10033464 (4q25, <italic>PITX2</italic>) displayed a risk estimate in the opposite direction than had been previously reported by others. This discrepancy appears to be in part due to linkage disequilibrium between this marker and the nearby SNP with the strongest association in this gene, rs2200733 (<italic>p =</italic> 0.005). We and others have observed that the risk alleles at these markers are negatively associated with each other. There remains uncertainty in the optimal genetic risk model for AF, and superior models will certainly evolve in the future as more genetic discoveries are made. In this light, we also considered a modified AF GRS that included only the most strongly associated SNP in each gene&#x02014;which is a common solution in GRS estimation to eliminate confounding due to linkage disequilibrium [<xref rid="pmed.1002525.ref032" ref-type="bibr">32</xref>]. The resulting 9-SNP model included rs2200733 for <italic>PITX2</italic> and the other 8 SNPs from the other genes. The risk of AF with this modified AF GRS, as in the 12-SNP model, was greater for the highest AF GRS quintile than for the lowest AF GRS quintile (OR 5.07; 95% CI 2.04&#x02013;12.60; <italic>p</italic> &#x0003c; 0.001), and this model appeared to better differentiate risk of AF throughout the distribution of genetic risk (<xref ref-type="supplementary-material" rid="pmed.1002525.s006">S3 Table</xref>). As expected, the risk estimates derived for both AF GRS models remained significant in an analysis limited to participants who self-reported as white (<xref ref-type="supplementary-material" rid="pmed.1002525.s007">S4 Table</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec017"><title>Discussion</title><p>We aimed to assess the ability of a previously developed AF GRS comprising 12 common SNPs (minor allele frequency &#x0003e; 5%) that have been found to be associated with AF at a genome-wide significance level to identify patients at the highest risk of developing AF in a prospective manner. Indeed, in this cohort of 904 participants of predominantly white ethnicity, 85 had AF events, and participants in the highest quintile of AF GRS had a risk greater than 3 times that of participants in the lowest AF GRS quintile. These findings are consistent with the original report [<xref rid="pmed.1002525.ref027" ref-type="bibr">27</xref>] of this specific AF GRS, in addition to other studies utilizing a multi-allele GRS [<xref rid="pmed.1002525.ref026" ref-type="bibr">26</xref>,<xref rid="pmed.1002525.ref028" ref-type="bibr">28</xref>]; however, all of these studies were conducted on a retrospective basis.</p><p>By harnessing advanced technology to realize the benefits of long-term cardiac rhythm monitoring using an adhesive patch monitor in lieu of the dated 24-hour Holter monitor [<xref rid="pmed.1002525.ref033" ref-type="bibr">33</xref>], participants were monitored for over 10 days after presenting to a clinic with specific symptoms prompting cardiac rhythm monitoring with a suspicion for AF. It has become clear that extended periods of ambulatory cardiac rhythm monitoring increase the yield of AF detection, especially in patients with cryptogenic stroke [<xref rid="pmed.1002525.ref034" ref-type="bibr">34</xref>]. AF is the most common arrhythmia, and with age being an important risk factor, its prevalence is estimated to increase steadily as humans live longer and with more chronic disease. While documented AF accounts for 1 out of every 6 strokes, a quarter of all strokes are initially categorized as &#x0201c;cryptogenic&#x0201d; with no identifiable cause. With prolonged rhythm monitoring strategies, many of these cryptogenic strokes are subsequently attributed to AF [<xref rid="pmed.1002525.ref012" ref-type="bibr">12</xref>,<xref rid="pmed.1002525.ref034" ref-type="bibr">34</xref>&#x02013;<xref rid="pmed.1002525.ref036" ref-type="bibr">36</xref>]. An AF GRS may help identify individuals at the highest risk of subclinical and paroxysmal AF who would benefit from a cardiac rhythm monitoring strategy even before a devastating stoke event. Improving identification of patients with AF, and initiating appropriate anticoagulant therapies when appropriate, is important given the risk of embolic stroke, which is more likely to be associated with major neurological deficits than non-embolic stroke [<xref rid="pmed.1002525.ref037" ref-type="bibr">37</xref>].</p><p>To date, the relative risk of AF associated with individual SNPs ranges from just above 1 to a highest value of 1.64 (rs6817105, <italic>PITX2</italic>). Thus, the ability to combine common SNPs into an AF GRS with the ability to differentiate a greater than 3-fold increased risk of AF in a population on a prospective basis may be useful. Such a panel of SNPs could be assayed at low cost and be used in conjunction with an evaluation of a patient with possible AF. For example, even 10 days of patch-based monitoring may not yield the diagnosis of subclinical AF and indicate that additional monitoring would be useful [<xref rid="pmed.1002525.ref034" ref-type="bibr">34</xref>,<xref rid="pmed.1002525.ref035" ref-type="bibr">35</xref>].</p><p>Several limitations of our study should be examined. Despite our efforts to recruit patients from various geographic regions across the US and Canada ranging from rural to urban settings, the vast majority of participants (93%) self-reported as white, with only minor representation from other ethnicities. The bulk of our understanding of genetic variants in association with disease has come from GWASs in populations of European ancestry, such that considerable assessment in other ancestries is important, and the 12-SNP panel we used in the study cannot be extrapolated beyond those of European ancestry [<xref rid="pmed.1002525.ref038" ref-type="bibr">38</xref>,<xref rid="pmed.1002525.ref039" ref-type="bibr">39</xref>]. With the inclusion of more ethnically diverse populations in genetic studies, the importance of ethnicity in determining the association of SNPs with disease will be magnified and will certainly need to be accounted for in future GRS calculations [<xref rid="pmed.1002525.ref040" ref-type="bibr">40</xref>,<xref rid="pmed.1002525.ref041" ref-type="bibr">41</xref>]. It was recently shown that rs10824026 (10q22), 1 of the SNPs utilized in the current AF GRS, conferred a greater risk for AF in white individuals than in black individuals [<xref rid="pmed.1002525.ref042" ref-type="bibr">42</xref>]. Although the current study is underpowered to assess AF risk by ethnicity, self-identified African-American participants in this study were far more likely to carry the risk allele (G) (53% GA and 38% GG) compared to self-identified white participants (26% GA and 2% GG).</p><p>Since the initiation of our study, additional SNPs associated with AF have been identified, and we expect this trend to continue as the genetic datasets expand. Our AF GRS did not include 5 recently discovered SNPs [<xref rid="pmed.1002525.ref043" ref-type="bibr">43</xref>], though 1 of these SNPs was specific for a Japanese population and the others had lower relative risks than the SNPs already included in our AF GRS. Additionally, our preliminary finding that demonstrated greater differentiation in AF based on a 9-SNP (1 SNP per gene) model simply shows that improvements can be made. Future efforts in developing polygenetic risk predictors of AF should focus on optimizing the set of markers and, potentially, population-specific weights assigned to individual markers. Yet, improving the predictive performance of a risk score solely based on genetic data will reach an upper limit [<xref rid="pmed.1002525.ref044" ref-type="bibr">44</xref>]. As additional AF biomarkers are determined through multi-omics approaches (proteomics, lipidomics, and metabolomics) or multiparameter physiological sensors, the addition of more complex clinical, physiological, and biomarker components to the AF GRS will be an exciting next step to developing a comprehensive AF risk score.</p><p>In terms of AF events, the mean monitoring time for patients evaluated with adhesive patch monitoring was less than 11 days, and there could have been patients for whom we did not capture their AF event during this time. Prolonged monitoring periods, as have been achieved using implantable monitoring devices, have been shown to detect increasingly more AF events over time, especially in patients with cryptogenic stroke [<xref rid="pmed.1002525.ref034" ref-type="bibr">34</xref>&#x02013;<xref rid="pmed.1002525.ref036" ref-type="bibr">36</xref>]. Currently, there is little guidance regarding optimal length of monitoring. While we do not feel that the future of diagnostic ambulatory cardiac rhythm monitoring is grounded in expensive, implantable devices, this role may instead be filled using unobtrusive and passive wearables. A SNP-based AF GRS, however, provides a fixed overall lifetime genetic risk assessment for AF, and given the short-term follow-up time in the current study, we expect that the ability of the AF GRS to identify individuals with the highest AF risk would likely increase with a longer monitoring period and follow-up. Likewise, we illustrate the strength of a GRS-based approach to disease screening and demonstrate the ability of the AF GRS to temporally stratify symptomatic patients with the probability of an AF diagnosis during 2 weeks of rhythm monitoring. In doing so, we have moved from the typical retrospective GWAS, without temporal association, to a prospective GRS screen that leverages the genomic risk for an individual under evaluation.</p><p>In conclusion, we prospectively validated a GRS for AF that may prove useful in the diagnostic evaluation of certain individuals who are being assessed for subclinical presence of this arrhythmia, and potentially as a means to help its prevention in the future.</p></sec><sec sec-type="supplementary-material" id="sec018"><title>Supporting information</title><supplementary-material content-type="local-data" id="pmed.1002525.s001"><label>S1 Checklist</label><caption><title>TRIPOD checklist.</title><p>(PDF)</p></caption><media xlink:href="pmed.1002525.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s002"><label>S1 Text</label><caption><title>Reported SNPs for study population.</title><p>(DOCX)</p></caption><media xlink:href="pmed.1002525.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s003"><label>S1 Protocol</label><caption><title>Study protocol.</title><p>(PDF)</p></caption><media xlink:href="pmed.1002525.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s004"><label>S1 Table</label><caption><title>US and Canadian patient recruitment centers.</title><p>(PDF)</p></caption><media xlink:href="pmed.1002525.s004.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s005"><label>S2 Table</label><caption><title>Performance of the individual SNPs of the AF GRS.</title><p>(PDF)</p></caption><media xlink:href="pmed.1002525.s005.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s006"><label>S3 Table</label><caption><title>Risk estimates of AF events according to AF GRS quintile (9-SNP model).</title><p>(PDF)</p></caption><media xlink:href="pmed.1002525.s006.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s007"><label>S4 Table</label><caption><title>Risk estimates for both the 12-SNP and 9-SNP AF GRS.</title><p>(PDF)</p></caption><media xlink:href="pmed.1002525.s007.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>This study could not have been done without the selflessness and generosity of our patients, who deserve our greatest appreciation. Additionally, we thank the many research coordinators, nurses, and physicians at each of the clinical enrollment sites for their support of this study. Adhesive patch monitors were kindly supplied by iRhythm Technologies.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>AF</term><def><p>atrial fibrillation</p></def></def-item><def-item><term>ECG</term><def><p>electrocardiogram</p></def></def-item><def-item><term>GRS</term><def><p>genetic risk score</p></def></def-item><def-item><term>GWAS</term><def><p>genome-wide association study</p></def></def-item><def-item><term>OR</term><def><p>odds ratio</p></def></def-item><def-item><term>SNP</term><def><p>single nucleotide polymorphism</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pmed.1002525.ref001"><label>1</label><mixed-citation publication-type="journal"><collab>Writing Group Members</collab>, <name><surname>Mozaffarian</surname><given-names>D</given-names></name>, <name><surname>Benjamin</surname><given-names>EJ</given-names></name>, <name><surname>Go</surname><given-names>AS</given-names></name>, <name><surname>Arnett</surname><given-names>DK</given-names></name>, <name><surname>Blaha</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>Heart disease and stroke statistics&#x02014;2016 update: a report from the American Heart Association</article-title>. <source>Circulation</source>. <year>2016</year>;<volume>133</volume>: <fpage>e38</fpage>&#x02013;<lpage>360</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIR.0000000000000350">10.1161/CIR.0000000000000350</ext-link></comment>
<?supplied-pmid 26673558?><pub-id pub-id-type="pmid">26673558</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Healey</surname><given-names>JS</given-names></name>, <name><surname>Connolly</surname><given-names>SJ</given-names></name>, <name><surname>Gold</surname><given-names>MR</given-names></name>, <name><surname>Israel</surname><given-names>CW</given-names></name>, <name><surname>Van Gelder</surname><given-names>IC</given-names></name>, <name><surname>Capucci</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Subclinical atrial fibrillation and the risk of stroke</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>:<fpage>120</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1105575">10.1056/NEJMoa1105575</ext-link></comment>
<?supplied-pmid 22236222?><pub-id pub-id-type="pmid">22236222</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Wolf</surname><given-names>PA</given-names></name>, <name><surname>Kannel</surname><given-names>WB</given-names></name>, <name><surname>Thomas</surname><given-names>HE</given-names></name>, <name><surname>Dawber</surname><given-names>TR</given-names></name>. <article-title>Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study</article-title>. <source>Neurology</source>. <year>1978</year>;<volume>28</volume>:<fpage>973</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 570666?><pub-id pub-id-type="pmid">570666</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Wolf</surname><given-names>PA</given-names></name>, <name><surname>Abbott</surname><given-names>RD</given-names></name>, <name><surname>Kannel</surname><given-names>WB</given-names></name>. <article-title>Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study</article-title>. <source>Arch Intern Med</source>. <year>1987</year>;<volume>147</volume>:<fpage>1561</fpage>&#x02013;<lpage>4</lpage>. <?supplied-pmid 3632164?><pub-id pub-id-type="pmid">3632164</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Colilla</surname><given-names>S</given-names></name>, <name><surname>Crow</surname><given-names>A</given-names></name>, <name><surname>Petkun</surname><given-names>W</given-names></name>, <name><surname>Singer</surname><given-names>DE</given-names></name>, <name><surname>Simon</surname><given-names>T</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>. <article-title>Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population</article-title>. <source>Am J Cardiol</source>. <year>2013</year>;<volume>112</volume>:<fpage>1142</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjcard.2013.05.063">10.1016/j.amjcard.2013.05.063</ext-link></comment>
<?supplied-pmid 23831166?><pub-id pub-id-type="pmid">23831166</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Glotzer</surname><given-names>TV</given-names></name>, <name><surname>Hellkamp</surname><given-names>AS</given-names></name>, <name><surname>Zimmerman</surname><given-names>J</given-names></name>, <name><surname>Sweeney</surname><given-names>MO</given-names></name>, <name><surname>Yee</surname><given-names>R</given-names></name>, <name><surname>Marinchak</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST)</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>1614</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.CIR.0000057981.70380.45">10.1161/01.CIR.0000057981.70380.45</ext-link></comment>
<?supplied-pmid 12668495?><pub-id pub-id-type="pmid">12668495</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Glotzer</surname><given-names>TV</given-names></name>, <name><surname>Daoud</surname><given-names>EG</given-names></name>, <name><surname>Wyse</surname><given-names>DG</given-names></name>, <name><surname>Singer</surname><given-names>DE</given-names></name>, <name><surname>Ezekowitz</surname><given-names>MD</given-names></name>, <name><surname>Hilker</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study</article-title>. <source>Circ Arrhythm Electrophysiol</source>. <year>2009</year>;<volume>2</volume>:<fpage>474</fpage>&#x02013;<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCEP.109.849638">10.1161/CIRCEP.109.849638</ext-link></comment>
<?supplied-pmid 19843914?><pub-id pub-id-type="pmid">19843914</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Kaasenbrood</surname><given-names>F</given-names></name>, <name><surname>Hollander</surname><given-names>M</given-names></name>, <name><surname>Rutten</surname><given-names>FH</given-names></name>, <name><surname>Gerhards</surname><given-names>LJ</given-names></name>, <name><surname>Hoes</surname><given-names>AW</given-names></name>, <name><surname>Tieleman</surname><given-names>RG</given-names></name>. <article-title>Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination</article-title>. <source>Europace</source>. <year>2016</year>;<volume>18</volume>:<fpage>1514</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/europace/euv426">10.1093/europace/euv426</ext-link></comment>
<?supplied-pmid 26851813?><pub-id pub-id-type="pmid">26851813</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>N</given-names></name>, <name><surname>Choy</surname><given-names>C</given-names></name>. <article-title>Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram</article-title>. <source>Heart</source>. <year>2017</year>;<volume>103</volume>:<fpage>24</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/heartjnl-2016-309993">10.1136/heartjnl-2016-309993</ext-link></comment>
<?supplied-pmid 27733533?><pub-id pub-id-type="pmid">27733533</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Lowres</surname><given-names>N</given-names></name>, <name><surname>Neubeck</surname><given-names>L</given-names></name>, <name><surname>Salkeld</surname><given-names>G</given-names></name>, <name><surname>Krass</surname><given-names>I</given-names></name>, <name><surname>McLachlan</surname><given-names>AJ</given-names></name>, <name><surname>Redfern</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study</article-title>. <source>Thromb Haemost</source>. <year>2014</year>;<volume>111</volume>:<fpage>1167</fpage>&#x02013;<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1160/TH14-03-0231">10.1160/TH14-03-0231</ext-link></comment>
<?supplied-pmid 24687081?><pub-id pub-id-type="pmid">24687081</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Svennberg</surname><given-names>E</given-names></name>, <name><surname>Engdahl</surname><given-names>J</given-names></name>, <name><surname>Al-Khalili</surname><given-names>F</given-names></name>, <name><surname>Friberg</surname><given-names>L</given-names></name>, <name><surname>Frykman</surname><given-names>V</given-names></name>, <name><surname>Rosenqvist</surname><given-names>M</given-names></name>. <article-title>Mass screening for untreated atrial fibrillation: the STROKESTOP study</article-title>. <source>Circulation</source>. <year>2015</year>;<volume>131</volume>:<fpage>2176</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.114.014343">10.1161/CIRCULATIONAHA.114.014343</ext-link></comment>
<?supplied-pmid 25910800?><pub-id pub-id-type="pmid">25910800</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Hess</surname><given-names>PL</given-names></name>, <name><surname>Healey</surname><given-names>JS</given-names></name>, <name><surname>Granger</surname><given-names>CB</given-names></name>, <name><surname>Connolly</surname><given-names>SJ</given-names></name>, <name><surname>Ziegler</surname><given-names>PD</given-names></name>, <name><surname>Alexander</surname><given-names>JH</given-names></name>, <etal>et al</etal>
<article-title>the role of cardiovascular implantable electronic devices in the detection and treatment of subclinical atrial fibrillation</article-title>. <source>JAMA Cardiol</source>. <year>2017</year>;;<volume>2</volume>:<fpage>324</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2016.5167">10.1001/jamacardio.2016.5167</ext-link></comment>
<?supplied-pmid 28097334?><pub-id pub-id-type="pmid">28097334</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Alonso</surname><given-names>A</given-names></name>, <name><surname>Norby</surname><given-names>FL</given-names></name>. <article-title>Predicting atrial fibrillation and its complications</article-title>. <source>Circ J</source>. <year>2016</year>;<volume>80</volume>:<fpage>1061</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1253/circj.CJ-16-0239">10.1253/circj.CJ-16-0239</ext-link></comment>
<?supplied-pmid 27008924?><pub-id pub-id-type="pmid">27008924</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Christophersen</surname><given-names>IE</given-names></name>, <name><surname>Yin</surname><given-names>X</given-names></name>, <name><surname>Larson</surname><given-names>MG</given-names></name>, <name><surname>Lubitz</surname><given-names>SA</given-names></name>, <name><surname>Magnani</surname><given-names>JW</given-names></name>, <name><surname>McManus</surname><given-names>DD</given-names></name>, <etal>et al</etal>
<article-title>A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study</article-title>. <source>Am Heart J</source>. <year>2016</year>;<volume>178</volume>:<fpage>45</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ahj.2016.05.004">10.1016/j.ahj.2016.05.004</ext-link></comment>
<?supplied-pmid 27502851?><pub-id pub-id-type="pmid">27502851</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Kolek</surname><given-names>MJ</given-names></name>, <name><surname>Graves</surname><given-names>AJ</given-names></name>, <name><surname>Xu</surname><given-names>M</given-names></name>, <name><surname>Bian</surname><given-names>A</given-names></name>, <name><surname>Teixeira</surname><given-names>PL</given-names></name>, <name><surname>Shoemaker</surname><given-names>MB</given-names></name>, <etal>et al</etal>
<article-title>Evaluation of a prediction model for the development of atrial fibrillation in a repository of electronic medical records</article-title>. <source>JAMA Cardiol</source>. <year>2016</year>;<volume>1</volume>:<fpage>1007</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2016.3366">10.1001/jamacardio.2016.3366</ext-link></comment>
<?supplied-pmid 27732699?><pub-id pub-id-type="pmid">27732699</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Lubitz</surname><given-names>SA</given-names></name>, <name><surname>Yin</surname><given-names>X</given-names></name>, <name><surname>Fontes</surname><given-names>JD</given-names></name>, <name><surname>Magnani</surname><given-names>JW</given-names></name>, <name><surname>Rienstra</surname><given-names>M</given-names></name>, <name><surname>Pai</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Association between familial atrial fibrillation and risk of new-onset atrial fibrillation</article-title>. <source>JAMA</source>. <year>2010</year>;<volume>304</volume>:<fpage>2263</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2010.1690">10.1001/jama.2010.1690</ext-link></comment>
<?supplied-pmid 21076174?><pub-id pub-id-type="pmid">21076174</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name>, <name><surname>Arnar</surname><given-names>DO</given-names></name>, <name><surname>Helgadottir</surname><given-names>A</given-names></name>, <name><surname>Gretarsdottir</surname><given-names>S</given-names></name>, <name><surname>Holm</surname><given-names>H</given-names></name>, <name><surname>Sigurdsson</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Variants conferring risk of atrial fibrillation on chromosome 4q25</article-title>. <source>Nature</source>. <year>2007</year>;<volume>448</volume>:<fpage>353</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature06007">10.1038/nature06007</ext-link></comment>
<?supplied-pmid 17603472?><pub-id pub-id-type="pmid">17603472</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Lubitz</surname><given-names>SA</given-names></name>, <name><surname>Sinner</surname><given-names>MF</given-names></name>, <name><surname>Lunetta</surname><given-names>KL</given-names></name>, <name><surname>Makino</surname><given-names>S</given-names></name>, <name><surname>Pfeufer</surname><given-names>A</given-names></name>, <name><surname>Rahman</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Independent susceptibility markers for atrial fibrillation on chromosome 4q25</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>122</volume>:<fpage>976</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.109.886440">10.1161/CIRCULATIONAHA.109.886440</ext-link></comment>
<?supplied-pmid 20733104?><pub-id pub-id-type="pmid">20733104</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Benjamin</surname><given-names>EJ</given-names></name>, <name><surname>Rice</surname><given-names>KM</given-names></name>, <name><surname>Arking</surname><given-names>DE</given-names></name>, <name><surname>Pfeufer</surname><given-names>A</given-names></name>, <name><surname>van Noord</surname><given-names>C</given-names></name>, <name><surname>Smith</surname><given-names>AV</given-names></name>, <etal>et al</etal>
<article-title>Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry</article-title>. <source>Nat Genet</source>. <year>2009</year>;<volume>41</volume>:<fpage>879</fpage>&#x02013;<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.416">10.1038/ng.416</ext-link></comment>
<?supplied-pmid 19597492?><pub-id pub-id-type="pmid">19597492</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Ellinor</surname><given-names>PT</given-names></name>, <name><surname>Lunetta</surname><given-names>KL</given-names></name>, <name><surname>Glazer</surname><given-names>NL</given-names></name>, <name><surname>Pfeufer</surname><given-names>A</given-names></name>, <name><surname>Alonso</surname><given-names>A</given-names></name>, <name><surname>Chung</surname><given-names>MK</given-names></name>, <etal>et al</etal>
<article-title>Common variants in KCNN3 are associated with lone atrial fibrillation</article-title>. <source>Nat Genet</source>. <year>2010</year>;<volume>42</volume>:<fpage>240</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.537">10.1038/ng.537</ext-link></comment>
<?supplied-pmid 20173747?><pub-id pub-id-type="pmid">20173747</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Ellinor</surname><given-names>PT</given-names></name>, <name><surname>Lunetta</surname><given-names>KL</given-names></name>, <name><surname>Albert</surname><given-names>CM</given-names></name>, <name><surname>Glazer</surname><given-names>NL</given-names></name>, <name><surname>Ritchie</surname><given-names>MD</given-names></name>, <name><surname>Smith</surname><given-names>AV</given-names></name>, <etal>et al</etal>
<article-title>Meta-analysis identifies six new susceptibility loci for atrial fibrillation</article-title>. <source>Nat Genet</source>. <year>2012</year>;<volume>44</volume>:<fpage>670</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.2261">10.1038/ng.2261</ext-link></comment>
<?supplied-pmid 22544366?><pub-id pub-id-type="pmid">22544366</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Christophersen</surname><given-names>IE</given-names></name>, <name><surname>Rienstra</surname><given-names>M</given-names></name>, <name><surname>Roselli</surname><given-names>C</given-names></name>, <name><surname>Yin</surname><given-names>X</given-names></name>, <name><surname>Geelhoed</surname><given-names>B</given-names></name>, <name><surname>Barnard</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation</article-title>. <source>Nat Genet</source>. <year>2017</year>;<volume>49</volume>:<fpage>946</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.3843">10.1038/ng.3843</ext-link></comment>
<?supplied-pmid 28416818?><pub-id pub-id-type="pmid">28416818</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Tucker</surname><given-names>NR</given-names></name>, <name><surname>Clauss</surname><given-names>S</given-names></name>, <name><surname>Ellinor</surname><given-names>PT</given-names></name>. <article-title>Common variation in atrial fibrillation: navigating the path from genetic association to mechanism</article-title>. <source>Cardiovasc Res</source>. <year>2016</year>;<volume>109</volume>:<fpage>493</fpage>&#x02013;<lpage>501</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cvr/cvv283">10.1093/cvr/cvv283</ext-link></comment>
<?supplied-pmid 26733238?><pub-id pub-id-type="pmid">26733238</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Goldstein</surname><given-names>BA</given-names></name>, <name><surname>Yang</surname><given-names>L</given-names></name>, <name><surname>Salfati</surname><given-names>E</given-names></name>, <name><surname>Assimes</surname><given-names>TL</given-names></name>. <article-title>Contemporary considerations for constructing a genetic risk score: an empirical approach</article-title>. <source>Genet Epidemiol</source>. <year>2015</year>;<volume>39</volume>:<fpage>439</fpage>&#x02013;<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/gepi.21912">10.1002/gepi.21912</ext-link></comment>
<?supplied-pmid 26198599?><pub-id pub-id-type="pmid">26198599</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>JA</given-names></name>, <name><surname>Ware</surname><given-names>EB</given-names></name>, <name><surname>Middha</surname><given-names>P</given-names></name>, <name><surname>Beacher</surname><given-names>L</given-names></name>, <name><surname>Kardia</surname><given-names>SLR</given-names></name>. <article-title>Current applications of genetic risk scores to cardiovascular outcomes and subclinical phenotypes</article-title>. <source>Curr Epidemiol Rep</source>. <year>2015</year>;<volume>2</volume>:<fpage>180</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40471-015-0046-4">10.1007/s40471-015-0046-4</ext-link></comment>
<?supplied-pmid 26269782?><pub-id pub-id-type="pmid">26269782</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Everett</surname><given-names>BM</given-names></name>, <name><surname>Cook</surname><given-names>NR</given-names></name>, <name><surname>Conen</surname><given-names>D</given-names></name>, <name><surname>Chasman</surname><given-names>DI</given-names></name>, <name><surname>Ridker</surname><given-names>PM</given-names></name>, <name><surname>Albert</surname><given-names>CM</given-names></name>. <article-title>Novel genetic markers improve measures of atrial fibrillation risk prediction</article-title>. <source>Eur Heart J</source>. <year>2013</year>;<volume>34</volume>:<fpage>2243</fpage>&#x02013;<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/eht033">10.1093/eurheartj/eht033</ext-link></comment>
<?supplied-pmid 23444395?><pub-id pub-id-type="pmid">23444395</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Tada</surname><given-names>H</given-names></name>, <name><surname>Shiffman</surname><given-names>D</given-names></name>, <name><surname>Smith</surname><given-names>JG</given-names></name>, <name><surname>Sj&#x000f6;gren</surname><given-names>M</given-names></name>, <name><surname>Lubitz</surname><given-names>SA</given-names></name>, <name><surname>Ellinor</surname><given-names>PT</given-names></name>, <etal>et al</etal>
<article-title>Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke</article-title>. <source>Stroke</source>. <year>2014</year>;<volume>45</volume>:<fpage>2856</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.114.006072">10.1161/STROKEAHA.114.006072</ext-link></comment>
<?supplied-pmid 25123217?><pub-id pub-id-type="pmid">25123217</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Lubitz</surname><given-names>SA</given-names></name>, <name><surname>Lunetta</surname><given-names>KL</given-names></name>, <name><surname>Lin</surname><given-names>H</given-names></name>, <name><surname>Arking</surname><given-names>DE</given-names></name>, <name><surname>Trompet</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>63</volume>:<fpage>1200</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jacc.2013.12.015">10.1016/j.jacc.2013.12.015</ext-link></comment>
<?supplied-pmid 24486271?><pub-id pub-id-type="pmid">24486271</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Lubitz</surname><given-names>SA</given-names></name>, <name><surname>Yin</surname><given-names>X</given-names></name>, <name><surname>Lin</surname><given-names>HJ</given-names></name>, <name><surname>Kolek</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>JG</given-names></name>, <name><surname>Trompet</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Genetic risk prediction of atrial fibrillation</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>135</volume>:<fpage>1311</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.116.024143">10.1161/CIRCULATIONAHA.116.024143</ext-link></comment>
<?supplied-pmid 27793994?><pub-id pub-id-type="pmid">27793994</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Schnabel</surname><given-names>RB</given-names></name>, <name><surname>Sullivan</surname><given-names>LM</given-names></name>, <name><surname>Levy</surname><given-names>D</given-names></name>, <name><surname>Pencina</surname><given-names>MJ</given-names></name>, <name><surname>Massaro</surname><given-names>JM</given-names></name>, <name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names></name>, <etal>et al</etal>
<article-title>Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>373</volume>:<fpage>739</fpage>&#x02013;<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(09)60443-8">10.1016/S0140-6736(09)60443-8</ext-link></comment>
<?supplied-pmid 19249635?><pub-id pub-id-type="pmid">19249635</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Liao</surname><given-names>J</given-names></name>, <name><surname>Khalid</surname><given-names>Z</given-names></name>, <name><surname>Scallan</surname><given-names>C</given-names></name>, <name><surname>Morillo</surname><given-names>C</given-names></name>, <name><surname>O&#x02019;Donnell</surname><given-names>M</given-names></name>. <article-title>Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>:<fpage>2935</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.106.478685">10.1161/STROKEAHA.106.478685</ext-link></comment>
<?supplied-pmid 17901394?><pub-id pub-id-type="pmid">17901394</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Mega</surname><given-names>JL</given-names></name>, <name><surname>Stitziel</surname><given-names>NO</given-names></name>, <name><surname>Smith</surname><given-names>JG</given-names></name>, <name><surname>Chasman</surname><given-names>DI</given-names></name>, <name><surname>Caulfield</surname><given-names>MJ</given-names></name>, <name><surname>Devlin</surname><given-names>JJ</given-names></name>, <etal>et al</etal>
<article-title>Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>385</volume>:<fpage>2264</fpage>&#x02013;<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(14)61730-X">10.1016/S0140-6736(14)61730-X</ext-link></comment>
<?supplied-pmid 25748612?><pub-id pub-id-type="pmid">25748612</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>PM</given-names></name>, <name><surname>Komatireddy</surname><given-names>R</given-names></name>, <name><surname>Haaser</surname><given-names>S</given-names></name>, <name><surname>Topol</surname><given-names>S</given-names></name>, <name><surname>Sheard</surname><given-names>J</given-names></name>, <name><surname>Encinas</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring</article-title>. <source>Am J Med</source>. <year>2014</year>;<volume>127</volume>:<fpage>95.e11</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pmed.1002525.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Sanna</surname><given-names>T</given-names></name>, <name><surname>Diener</surname><given-names>H-C</given-names></name>, <name><surname>Passman</surname><given-names>RS</given-names></name>, <name><surname>Di Lazzaro</surname><given-names>V</given-names></name>, <name><surname>Bernstein</surname><given-names>R a</given-names></name>, <name><surname>Morillo</surname><given-names>CA</given-names></name>, <etal>et al</etal>
<article-title>Cryptogenic stroke and underlying atrial fibrillation</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>:<fpage>2478</fpage>&#x02013;<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1313600">10.1056/NEJMoa1313600</ext-link></comment>
<?supplied-pmid 24963567?><pub-id pub-id-type="pmid">24963567</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Gladstone</surname><given-names>DJ</given-names></name>, <name><surname>Spring</surname><given-names>M</given-names></name>, <name><surname>Dorian</surname><given-names>P</given-names></name>, <name><surname>Panzov</surname><given-names>V</given-names></name>, <name><surname>Thorpe</surname><given-names>KE</given-names></name>, <name><surname>Hall</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Atrial fibrillation in patients with cryptogenic stroke</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>:<fpage>2467</fpage>&#x02013;<lpage>77</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1311376">10.1056/NEJMoa1311376</ext-link></comment>
<?supplied-pmid 24963566?><pub-id pub-id-type="pmid">24963566</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Kishore</surname><given-names>A</given-names></name>, <name><surname>Vail</surname><given-names>A</given-names></name>, <name><surname>Majid</surname><given-names>A</given-names></name>, <name><surname>Dawson</surname><given-names>J</given-names></name>, <name><surname>Lees</surname><given-names>KR</given-names></name>, <name><surname>Tyrrell</surname><given-names>PJ</given-names></name>, <etal>et al</etal>
<article-title>Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis</article-title>. <source>Stroke</source>. <year>2014</year>;<volume>45</volume>:<fpage>520</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.113.003433">10.1161/STROKEAHA.113.003433</ext-link></comment>
<?supplied-pmid 24385275?><pub-id pub-id-type="pmid">24385275</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Arboix</surname><given-names>A</given-names></name>, <name><surname>Ali&#x000f3;</surname><given-names>J</given-names></name>. <article-title>Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis</article-title>. <source>Curr Cardiol Rev</source>. <year>2010</year>;<volume>6</volume>:<fpage>150</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2174/157340310791658730">10.2174/157340310791658730</ext-link></comment>
<?supplied-pmid 21804774?><pub-id pub-id-type="pmid">21804774</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Popejoy</surname><given-names>AB</given-names></name>, <name><surname>Fullerton</surname><given-names>SM</given-names></name>. <article-title>Genomics is failing on diversity</article-title>. <source>Nature</source>. <year>2016</year>;<volume>538</volume>:<fpage>161</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/538161a">10.1038/538161a</ext-link></comment>
<?supplied-pmid 27734877?><pub-id pub-id-type="pmid">27734877</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Marcus</surname><given-names>GM</given-names></name>, <name><surname>Alonso</surname><given-names>A</given-names></name>, <name><surname>Peralta</surname><given-names>CA</given-names></name>, <name><surname>Lettre</surname><given-names>G</given-names></name>, <name><surname>Vittinghoff</surname><given-names>E</given-names></name>, <name><surname>Lubitz</surname><given-names>SA</given-names></name>, <etal>et al</etal>
<article-title>European ancestry as a risk factor for atrial fibrillation in African Americans</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>122</volume>:<fpage>2009</fpage>&#x02013;<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.110.958306">10.1161/CIRCULATIONAHA.110.958306</ext-link></comment>
<?supplied-pmid 21098467?><pub-id pub-id-type="pmid">21098467</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Manrai</surname><given-names>AK</given-names></name>, <name><surname>Funke</surname><given-names>BH</given-names></name>, <name><surname>Rehm</surname><given-names>HL</given-names></name>, <name><surname>Olesen</surname><given-names>MS</given-names></name>, <name><surname>Maron</surname><given-names>BA</given-names></name>, <name><surname>Szolovits</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Genetic misdiagnoses and the potential for health disparities</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>655</fpage>&#x02013;<lpage>65</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMsa1507092">10.1056/NEJMsa1507092</ext-link></comment>
<?supplied-pmid 27532831?><pub-id pub-id-type="pmid">27532831</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Rosenberg</surname><given-names>NA</given-names></name>, <name><surname>Huang</surname><given-names>L</given-names></name>, <name><surname>Jewett</surname><given-names>EM</given-names></name>, <name><surname>Szpiech</surname><given-names>ZA</given-names></name>, <name><surname>Jankovic</surname><given-names>I</given-names></name>, <name><surname>Boehnke</surname><given-names>M</given-names></name>. <article-title>Genome-wide association studies in diverse populations</article-title>. <source>Nat Rev Genet</source>. <year>2010</year>;<volume>11</volume>:<fpage>356</fpage>&#x02013;<lpage>66</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrg2760">10.1038/nrg2760</ext-link></comment>
<?supplied-pmid 20395969?><pub-id pub-id-type="pmid">20395969</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>JD</given-names></name>, <name><surname>Hu</surname><given-names>D</given-names></name>, <name><surname>Heckbert</surname><given-names>SR</given-names></name>, <name><surname>Alonso</surname><given-names>A</given-names></name>, <name><surname>Dewland</surname><given-names>TA</given-names></name>, <name><surname>Vittinghoff</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Genetic investigation into the differential risk of atrial fibrillation among black and white individuals</article-title>. <source>JAMA Cardiol</source>. <year>2016</year>;<volume>1</volume>:<fpage>442</fpage>&#x02013;<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2016.1185">10.1001/jamacardio.2016.1185</ext-link></comment>
<?supplied-pmid 27438321?><pub-id pub-id-type="pmid">27438321</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Sinner</surname><given-names>MF</given-names></name>, <name><surname>Tucker</surname><given-names>NR</given-names></name>, <name><surname>Lunetta</surname><given-names>KL</given-names></name>, <name><surname>Ozaki</surname><given-names>K</given-names></name>, <name><surname>Smith</surname><given-names>JG</given-names></name>, <name><surname>Trompet</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>130</volume>:<fpage>1225</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.114.009892">10.1161/CIRCULATIONAHA.114.009892</ext-link></comment>
<?supplied-pmid 25124494?><pub-id pub-id-type="pmid">25124494</pub-id></mixed-citation></ref><ref id="pmed.1002525.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Manolio</surname><given-names>TA</given-names></name>. <article-title>Bringing genome-wide association findings into clinical use</article-title>. <source>Nat Rev Genet</source>. <year>2013</year>;<volume>14</volume>:<fpage>549</fpage>&#x02013;<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrg3523">10.1038/nrg3523</ext-link></comment>
<?supplied-pmid 23835440?><pub-id pub-id-type="pmid">23835440</pub-id></mixed-citation></ref></ref-list></back></article>